The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Cytomegalovirus (CMV) Infection in Immunosuppressed Patients

Reactivation or primary CMV infection in transplant and HIV patients causing viremia, end-organ disease, and indirect immunomodulatory effects.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Internal Medicine department. Book Appointment →

What is Cytomegalovirus (CMV) Infection in Immunosuppressed Patients?

Cytomegalovirus (CMV) is a ubiquitous beta-herpesvirus with seroprevalence of 50–90% depending on geography. After primary infection (often subclinical) it establishes lifelong latency in myeloid lineage cells. Reactivation, reinfection, or primary infection in immunosuppressed patients causes substantial morbidity and mortality, especially after solid organ transplantation (SOT), hematopoietic stem cell transplantation (HSCT), advanced HIV, and biologic therapy.

Highest risk groups are CMV-seronegative recipients of seropositive organs (D+/R-) due to primary infection, allogeneic HSCT recipients with reactivation, lung and small bowel transplants, GVHD on intensified immunosuppression, alemtuzumab/ATG induction, and HIV with CD4 < 50. Direct effects include viremia, fever, leukopenia, pneumonitis, colitis, hepatitis, retinitis, encephalitis, and graft dysfunction. Indirect effects include increased acute rejection, accelerated atherosclerosis, opportunistic superinfection, and post-transplant lymphoproliferative disorder.

Diagnosis combines quantitative CMV PCR in blood (gold standard for monitoring), tissue PCR and histopathology with immunohistochemistry for end-organ disease, and ophthalmologic evaluation for retinitis. Management follows two strategies in transplant: universal prophylaxis with valganciclovir 900 mg daily for 100–200 days versus preemptive therapy guided by weekly PCR. Established disease is treated with IV ganciclovir 5 mg/kg q12h or oral valganciclovir 900 mg q12h for 14–21 days, followed by maintenance until clearance and reduction of immunosuppression.

Symptoms

Asymptomatic viremia (most common)
CMV syndrome: fever, fatigue, leukopenia, thrombocytopenia, transaminitis
CMV pneumonitis: fever, dyspnea, hypoxia, ground-glass opacities (especially HSCT)
CMV colitis: diarrhea, abdominal pain, GI bleeding, ulcerations
CMV hepatitis: transaminitis, jaundice (post-liver transplant)
CMV retinitis: floaters, vision loss, hemorrhagic retinitis (especially HIV)
CMV encephalitis: confusion, seizures (rare)
CMV nephritis in renal allograft
Tissue-invasive disease in any organ
Indirect effects: rejection, graft loss, opportunistic infection
Allograft dysfunction in lung, kidney, liver
Hematologic abnormalities mimicking GVHD or drug toxicity
Pancreatitis (rare)
Adrenalitis with adrenal insufficiency
Recurrent or persistent viremia despite therapy

Risk Factors

Donor seropositive, recipient seronegative (D+/R-) — highest risk
Allogeneic HSCT (especially mismatched, haploidentical, cord)
Lung, intestine, multivisceral transplant
GVHD requiring intensified immunosuppression
Lymphocyte-depleting induction (ATG, alemtuzumab)
Steroid pulse therapy for rejection
HIV with CD4 < 50
Hematologic malignancy with prolonged neutropenia
Inflammatory bowel disease on biologics with CMV reactivation
Critical illness (ICU)
Concurrent infections (e.g., HHV-6)
Older age
Underlying lymphoproliferative disorder
Repeat transplantation
Pre-transplant CMV viremia

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Fever in any post-transplant or HIV patient
  • Cytopenias on routine monitoring
  • Diarrhea, GI bleeding in transplant patient
  • Visual symptoms in advanced HIV or transplant
  • Pneumonia not responding to standard therapy in immunocompromised
  • Allograft dysfunction with rising creatinine, transaminases
  • Confusion or focal neurologic deficits in immunocompromised
  • Persistent viremia on prophylaxis
  • Suspected GVHD requiring CMV evaluation
  • Newly diagnosed HIV with retinitis or colitis

Treatment Methods

01
Quantitative CMV PCR in plasma or whole blood for diagnosis and monitoring
02
Tissue biopsy with histopathology and immunohistochemistry for tissue-invasive disease
03
Ophthalmology evaluation if visual symptoms
04
Define D/R serostatus and risk stratify all transplant candidates
05
Universal prophylaxis: valganciclovir 900 mg daily for 100-200 days in high-risk SOT (D+/R-)
06
HSCT preemptive therapy with weekly PCR and treatment threshold (varies by center)
07
Letermovir prophylaxis post allogeneic HSCT for 100-200 days (CMV-seropositive recipients)
08
Maribavir for refractory or resistant CMV with UL97 mutations
09
Treatment dose: IV ganciclovir 5 mg/kg q12h or valganciclovir 900 mg q12h for 14-21 days
10
Adjust dose for renal function
11
Monitor for ganciclovir-induced neutropenia, GCSF if needed
12
Foscarnet for ganciclovir-resistant disease (UL97 mutation), nephrotoxic
13
Cidofovir as third-line option, nephrotoxic and ocular toxicity
14
Reduce immunosuppression where possible
15
Treat until at least one negative PCR and clinical resolution
16
Maintenance therapy after disease in selected high-risk patients
17
Intravitreal ganciclovir or foscarnet for sight-threatening retinitis
18
Monitor for resistance with UL97/UL54 sequencing if poor response
19
CMV hyperimmune globulin in selected refractory cases
20
Long-term surveillance and patient education on warning signs

Which Department to Visit?

You can visit our Enfeksiyon Hastalıkları department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Enfeksiyon Hastalıkları Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Flu (Influenza)

Enfeksiyon Hastalıkları

Influenza is a seasonal contagious respiratory disease caused by influenza viruses; it presents with high fever, muscle pain, and severe fatigue.

COVID-19

Enfeksiyon Hastalıkları

COVID-19 is a contagious disease caused by the SARS-CoV-2 coronavirus with a wide clinical spectrum ranging from asymptomatic to severe pneumonia.

Upper Respiratory Tract Infection

Enfeksiyon Hastalıkları

Upper respiratory tract infections are diseases that include common cold, pharyngitis, sinusitis, and laryngitis, often of viral origin and self-limited.

Urinary Tract Infection

Enfeksiyon Hastalıkları

Urinary tract infections are common bacterial infections most often caused by Escherichia coli, presenting with burning and frequent urination.

Hepatitis A (HAV)

Enfeksiyon Hastalıkları

Hepatitis A is an acute, self-limited liver infection transmitted via the fecal-oral route causing acute hepatitis without chronicity; supportive care suffices in most cases, while vaccination prevents outbreaks and post-exposure prophylaxis within 2 weeks is effective.

Hepatitis B

Enfeksiyon Hastalıkları

Hepatitis B is a contagious infection caused by HBV virus transmitted via blood, sexual intercourse, and mother-to-child, that can become chronic and progress to cirrhosis and liver cancer.

Hepatitis C

Enfeksiyon Hastalıkları

Hepatitis C is a liver disease caused by HCV virus transmitted mainly by blood; the rate of chronicity is high, but cure is possible with new antiviral drugs.

HIV/AIDS Information

Enfeksiyon Hastalıkları

HIV is a virus that targets the immune system; if untreated, it progresses to AIDS. With modern antiretroviral therapy, HIV-positive individuals can lead healthy, long lives.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.